GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
Recruiting now · Phase 4
Conditions studied: Myocardial Injury
In brief
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery. Recruited patients will be randomized in a 2:1 ratio to receive single subcutaneous dose of Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RAs) 1 to 14 days prior to surgery or receive routine care. Dulaglutide (Trulicity; Eli Lilly, USA) is chosen as GLP-1 Receptor Agonists investigational drug for this study. Apart from peri-operative routine care, all recruited subjects will undergo physical, respiratory and cardiac assessments including electrocardiography and blood check including cardiac enzymes. Myocardial injury, cardiovascular outcomes and safety will be assessed and evaluated for efficacy and safety of this prophylactic measurement for the reduction of myocardial injury after non-cardiac surgery.
Key facts
- Study ID
- NCT06324461
- Run by
- The University of Hong Kong
- People needed
- 372
- Starts
- 2024-03-20
- Expected to finish
- 2028-12-31
- Last updated by the study team
- 2026-05-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years
- Planned elective intermediate to high risk non-cardiac surgery
- Anticipated to remain hospitalized for at least one night after surgery
- Voluntarily agrees to participate by providing written informed consent
You may not qualify if…
- History of symptomatic hypoglycemia within 1 month of recruitment
- History of pancreatitis
- Diabetic retinopathy
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment
- Stroke or transient ischemic attack within 1 month of recruitment
- Known severe liver disease (Child-Pugh B or C)
- Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation < 15 mL/min)
- Recent use of GLP-1 RA within 1 month of recruitment
- Known allergy or hypersensitivity to GLP-1 RA
- Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding
- Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)
Where it is running
- Queen Mary Hospital — Hong Kong, Hong Kong SAR, China (enrolling)
- Tung Wah Hospital — Hong Kong, Hong Kong SAR, China (enrolling)
- Duchess of Kent Children's Hospital at Sandy Bay — Hong Kong, Hong Kong SAR, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.